UNITED STATES 
SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549

Form 10-Q/A

(Mark One)

xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period endedSeptember 30, 2015or

□TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from__________ to _________ 
Commission File Number000-52534

[f20150930prlxform10qa001.jpg]

PARALLAX HEALTH SCIENCES, INC.(Exact name of registrant as specified in its charter)

|                                                               |                                     
|-------------------------------------------------------------- | ------------------------------------
|Nevada                                                         | 46-4733512                          
|(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.)
|                                                               |                                     
|1327 Ocean Avenue, Suite B, Santa Monica, CA                   | 90401                               
|(Address of principal executive offices)                       | (Zip Code)                          
|                                                               |                                     
|Registrant's telephone number, including area code:            | (310) 899-4442                      
|                                                               |                                     



Copy of all Communications to:

Lawrence I. Washor

Washor & Associates

21800 Oxnard Street, Suite 790

Woodland Hills, CA 91367

(310) 479-2660



Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.











□YESxNO

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

xYES□NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.



|                                              |   |  |                           |  
|--------------------------------------------- | - |  | ------------------------- | -
|Large accelerated filer                       | □ |  | Accelerated filer         | □
|Non-accelerated filer                         | □ |  | Smaller reporting company | x
|(Do not check if a smaller reporting company) |   |  |                          



Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)

□YESxNO



APPLICABLE ONLY TO CORPORATE ISSUERS



Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.



105,566,774 common shares issued and outstanding as of September 30, 2016











EXPLANATORY NOTE





This Amendment No. 1 to the Quarterly Report on Form 10-Q/A is being filed solely to correct the number of shares outstanding as of the last practicable date, above. No other changes have been made to the Form 10-Q, as originally filed on October 13, 2016.











SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

|                        |                                                
|----------------------- | -----------------------------------------------
|                        | PARALLAX HEALTH SCIENCES, INC.                 
|                        |                                                
|                        |                                                
|Dated: October 14, 2016 | /s/ J. Michael Redmond                         
|                        | J. Michael Redmond                             
|                        | President, Chief Executive Officer and Director
|                        |                                                
|                        |                                                
|                        |                                                
|Dated: October 14, 2016 | /s/ Calli Bucci                                
|                        | Calli Bucci                                    
|                        | Chief Financial Officer